Aclaris Therapeutics (ACRS) Consolidated Net Income (2014 - 2026)
Aclaris Therapeutics' quarterly Consolidated Net Income came in at -$20.7 million in Q1 2026, down 29.9% year-on-year from -$29.5 million in Q1 2025, and up 2.0% quarter-over-quarter from -$21.1 million in Q4 2025.
Aclaris Therapeutics has reported Consolidated Net Income for 13 years, with the latest figure at -$20.7 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income fell 29.9% year-over-year to -$20.7 million; the trailing twelve-month figure through Mar 2026 stood at -$73.5 million (up 44.72% YoY), and the FY2025 full-year result was -$68.7 million, up 47.95% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$20.7 million, up from -$21.1 million in the prior quarter.
- The five-year high for Consolidated Net Income was -$1.9 million in Q4 2023, with the low at -$97.6 million in Q4 2024.
- Average Consolidated Net Income over 5 years is -$23.9 million, with a median of -$20.7 million recorded in 2026.
- Year-over-year, Consolidated Net Income jumped 93.61% in 2023 and slumped 5151.45% in 2024.
- Tracing ACRS's Consolidated Net Income over 5 years: stood at -$29.1 million in 2022, then jumped by 93.61% to -$1.9 million in 2023, then tumbled by 5151.45% to -$97.6 million in 2024, then soared by 78.37% to -$21.1 million in 2025, then rose by 2.0% to -$20.7 million in 2026.
- The last three Consolidated Net Income figures came in at -$20.7 million (Q1 2026), -$21.1 million (Q4 2025), and -$15.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Aclaris Therapeutics | 586.09 Mn | 586.09 Mn | 1.60 Mn | -20.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.68 Mn |
| Dec 31, 2025 | -21.10 Mn |
| Sep 30, 2025 | -15.33 Mn |
| Jun 30, 2025 | -16.39 Mn |
| Mar 31, 2025 | -15.92 Mn |
| Dec 31, 2024 | -97.57 Mn |
| Sep 30, 2024 | -8.48 Mn |
| Jun 30, 2024 | -10.99 Mn |
| Mar 31, 2024 | -16.94 Mn |
| Dec 31, 2023 | -1.86 Mn |
| Sep 30, 2023 | -29.26 Mn |
| Jun 30, 2023 | -31.82 Mn |
| Mar 31, 2023 | -29.92 Mn |
| Dec 31, 2022 | -29.08 Mn |
| Sep 30, 2022 | -20.87 Mn |
| Jun 30, 2022 | -20.99 Mn |
| Mar 31, 2022 | -18.91 Mn |
| Dec 31, 2021 | -22.89 Mn |
| Sep 30, 2021 | -20.30 Mn |
| Jun 30, 2021 | -18.01 Mn |
| Mar 31, 2021 | -28.53 Mn |
| Dec 31, 2020 | 424,000.00 |
| Jun 30, 2020 | -27,000.00 |
| Mar 31, 2020 | -258,000.00 |
| Dec 31, 2019 | 854,000.00 |
| Sep 30, 2019 | -32.18 Mn |
| Jun 30, 2019 | -6.19 Mn |
| Mar 31, 2019 | -10.28 Mn |
| Dec 31, 2018 | -14.99 Mn |
| Sep 30, 2018 | -12.11 Mn |
| Jun 30, 2018 | -31.98 Mn |
| Mar 31, 2018 | -30.95 Mn |
| Dec 31, 2017 | -7.38 Mn |
| Sep 30, 2017 | -18.76 Mn |
| Jun 30, 2017 | -15.30 Mn |
| Mar 31, 2017 | -12.93 Mn |
| Dec 31, 2016 | -11.63 Mn |
| Sep 30, 2016 | -10.81 Mn |
| Jun 30, 2016 | -12.99 Mn |
| Mar 31, 2016 | -13.14 Mn |
| Dec 31, 2015 | -4.71 Mn |
| Sep 30, 2015 | -10.63 Mn |
| Jun 30, 2015 | -2.59 Mn |
| Mar 31, 2015 | -2.62 Mn |
| Dec 31, 2014 | -2.60 Mn |
| Sep 30, 2014 | -2.66 Mn |